Cargando…

ESR1 Methylation Measured in Cell-Free DNA to Evaluate Endocrine Resistance in Metastatic Breast Cancer Patients

ESR1 methylation was proposed as mechanism for endocrine resistance in metastatic breast cancer patients. To evaluate its potential as a minimally invasive biomarker, we investigated the feasibility of measuring ESR1 methylation in cell-free DNA (cfDNA) and its association with endocrine resistance....

Descripción completa

Detalles Bibliográficos
Autores principales:	Bos, Manouk K., Deger, Teoman, Sleijfer, Stefan, Martens, John W. M., Wilting, Saskia M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142900/ https://www.ncbi.nlm.nih.gov/pubmed/35628441 http://dx.doi.org/10.3390/ijms23105631

Ejemplares similares

A Systematic Review of the Use of Circulating Cell-Free DNA Dynamics to Monitor Response to Treatment in Metastatic Breast Cancer Patients
por: Jongbloed, Elisabeth M., et al.
Publicado: (2021)

Methylated Cell-Free DNA Sequencing (MeD-seq) of LpnPI Digested Fragments to Identify Early Progression in Metastatic Renal Cell Carcinoma Patients on Watchful Waiting
por: Bos, Manouk K., et al.
Publicado: (2023)

High-throughput and affordable genome-wide methylation profiling of circulating cell-free DNA by methylated DNA sequencing (MeD-seq) of LpnPI digested fragments
por: Deger, Teoman, et al.
Publicado: (2021)

Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
por: Verschoor, Noortje, et al.
Publicado: (2023)

Hypermethylation of DNA Methylation Markers in Non-Cirrhotic Hepatocellular Carcinoma
por: Fu, Siyu, et al.
Publicado: (2023)

Apolipoprotein B mRNA-Editing Catalytic Polypeptide-Like–Induced Protein Changes in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Throughout Disease Progression
por: Bos, Manouk K., et al.
Publicado: (2022)

Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer
por: Li, Zheqi, et al.
Publicado: (2022)

Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER Signaling
por: Angus, Lindsay, et al.
Publicado: (2023)

High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy
por: Lupini, Laura, et al.
Publicado: (2018)

A pipeline for copy number profiling of single circulating tumour cells to assess intrapatient tumour heterogeneity
por: Deger, Teoman, et al.
Publicado: (2022)

The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer
por: Vitale, Silvia R., et al.
Publicado: (2022)

Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer
por: Gou, Xuxu, et al.
Publicado: (2021)

CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients
por: Crucitta, Stefania, et al.
Publicado: (2023)

Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole
por: Gyanchandani, Rekha, et al.
Publicado: (2016)

mFast‐SeqS‐based aneuploidy score in circulating cell‐free DNA is a prognostic biomarker in prostate cancer
por: Isebia, Khrystany T., et al.
Publicado: (2023)

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer
por: Hartmaier, R J, et al.
Publicado: (2018)

Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival
por: Verschoor, Noortje, et al.
Publicado: (2023)

Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer
por: Bos, M. K., et al.
Publicado: (2023)

ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer
por: Lei, Jonathan T., et al.
Publicado: (2018)

Genome‐wide aneuploidy detected by mFast‐SeqS in circulating cell‐free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer
por: Mendelaar, Pauline A. J., et al.
Publicado: (2022)

ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis
por: Zundelevich, Adi, et al.
Publicado: (2020)

ESR1 mutations in metastatic lobular breast cancer patients
por: Desmedt, Christine, et al.
Publicado: (2019)

ESR1 fusions and therapeutic resistance in metastatic breast cancer
por: Nagy, Zsuzsanna, et al.
Publicado: (2023)

Lost by Transcription: Fork Failures, Elevated Expression, and Clinical Consequences Related to Deletions in Metastatic Colorectal Cancer
por: Smid, Marcel, et al.
Publicado: (2022)

Molecular Barcode Sequencing of the Whole Ligand Binding Domain of the ESR1 Gene in Cell-Free DNA from Patients with Metastatic Breast Cancer()
por: Masunaga, Nanae, et al.
Publicado: (2020)

Machine learning-based somatic variant calling in cell-free DNA of metastatic breast cancer patients using large NGS panels
por: Jongbloed, Elisabeth M., et al.
Publicado: (2023)

Correction to: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis
por: Zundelevich, Adi, et al.
Publicado: (2020)

Corrigendum: ESR1 fusions and therapeutic resistance in metastatic breast cancer
por: Nagy, Zsuzsanna, et al.
Publicado: (2023)

Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer
por: Sim, Sung Hoon, et al.
Publicado: (2021)

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance
por: Martin, Lesley-Ann, et al.
Publicado: (2017)

Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance
por: Li, Li, et al.
Publicado: (2020)

Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients
por: Martínez-Galán, Joaquina, et al.
Publicado: (2014)

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
por: Brett, Jamie O., et al.
Publicado: (2021)

Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer
por: Kuang, Yanan, et al.
Publicado: (2018)

The predictive ability of plasma ESR1 mutations for the efficacy of endocrine therapy in hormone-receptor-positive advanced breast cancer
por: Du, Yangfan, et al.
Publicado: (2018)

The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy
por: De Santo, Irene, et al.
Publicado: (2019)

Author Correction: Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

Updates in endocrine therapy for metastatic breast cancer
por: Manohar, Poorni M., et al.
Publicado: (2022)

Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA
por: Bos, Manouk K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a4m961q92idp6folbb6j0qmmi1